PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26966142-10	2016	However, sevoflurane pretreatment reduced the release of HS and Syn-1and attenuated the levels of ALT and AST, in a time-dependent manner, as compared with ketamine pretreatment.	Sevoflurane	9-20	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	106-109	
25105848-13	2014	RESULTS: Rats in the sevoflurane group had significantly lower concentrations of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and LDH in the samples obtained from the preservative solution after 6 h of cold ischaemia (P < 0.05).	Sevoflurane	21-32	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	81-107	
25105848-13	2014	RESULTS: Rats in the sevoflurane group had significantly lower concentrations of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and LDH in the samples obtained from the preservative solution after 6 h of cold ischaemia (P < 0.05).	Sevoflurane	21-32	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	109-112	
35433991-9	2022	Results: Compared to the IR group, the sevoflurane post-treatment or miR-122 antagomir groups showed improved liver injury, decreased Suzuki score, inhibited the levels of AST, ALT, LDH, MDA, NO, TNF-alpha, IL-1beta, and IL-6, increased levels of SOD, IL-10, and inhibited hepatocyte apoptosis.	Sevoflurane	39-50	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	172-175	
23702600-10	2013	RESULTS: Serum levels of aspartate aminotransferase and alanine aminotransferase in the sevoflurane groups were significantly reduced compared to the elevated levels seen in the I/R group (P < 0.05).	Sevoflurane	88-99	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	25-51